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Oral Presentations S191antagonist approved for the prevention of acute and delayed CINV
associated with initial and repeat courses of moderately and highly
emetogenic chemotherapy in combination with other antiemetics.
We evaluated the outcomes of ondansetron and dexamethasone
compared with aprepitant, ondansetron, and dexamethasone in pa-
tients undergoing autologous HSCT, with BEAM or Melphalan
conditioning, in a randomized single center clinical trial. Patients
were randomized to receive either ondansetron and dexamethasone
on the days of chemotherapy followed by 3 days of dexamethasone
(OD) or OD combined with aprepitant 125 mg on the first day of
conditioning, followed by aprepitant 80 mg daily until day
0 (AOD). Rescue antiemetics were allowed. Acute phase was
defined as each day (24-hr period) of chemotherapy. Delayed phase
was defined as the 5 days (0 – 120 hrs) following the last dose of
chemotherapy. Complete response (CR) was defined as no emesis
or rescue antiemetics in a 24-hour period. Major response (MaR)
was defined as 1 episode of emesis or the need for rescue anti-
emetics in a 24-hour period. Twenty-four patients were random-
ized to each arm. Age, gender, prior history of CINV, and
conditioning regimen were similar between OD and AOD. There
were no significant differences between the two arms in the rates
of acute or delayed nausea, CR, and MaR (Table 1). Despite pre-
medication, almost all of the patients experienced nausea and/or
vomiting after the completion of the study period up to day +30
(OD 100% and AOD 83.3%; p5 0.11). Grade 3/4 nonhematologic
toxicity was similar between the two groups. The most common
toxicities reported were nausea, hypophosphatemia, anorexia, and
infection. Although the CR rates for acute and delayed emesis
were greater in AOD, the addition of aprepitant did not signifi-
cantly improve CINV control in this small autologous HSCT
population.Table 1. Antiemetic Response Rates
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Background:The optimal dosing of MMF in pediatric AlloSCT re-
cipients is unknown.
Objective: To determine MMF PK in pediatric AlloSCT recipi-
ents\12 years of age.
Methods:GVHDprophylaxis included tacrolimusDay –1 (5-20 ng/
mL) and MMF 900 mg/m2 IV Q6H starting on Day +1, then con-
verted to PO (same dose) after Day +14. MPA serum samples were
drawn on Days +1, +7, +14 (IV phase) and twice between Day +45-
+100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose. MPA plasma
concentrations were determined by reverse-phase HPLC and LC/
MS/MS. Non-compartmental PK analysis of total MPA was
performed.
Results: PK was completed in 25 pts: mean age 5 yrs; M:F 12:13;
14 pts\6 yrs & 11 pts 6-12 yrs; 11 pts non-malignant & 14 with
malignant disease; 14 pts received unrelated AlloSCT. Patients
with non-malignant disease received reduced-intensity condition-
ing. Median time to myeloid and platelet engraftment was 21
and 33 days, respectively. KM probability of Grade II-IV acute
GVHD (aGVHD) and limited + extensive chronic GVHD was
52% and 39.8%, respectively. Probability of 1 year OS was
78.8% (CI95: 62%-95%). There was a significant inter- and intra-
patient variability in AUC0-6 and MPA trough (C0) (Table 1).
There was no significant difference in MMF PK between
pts\6 vs 6-12 yrs of age following IV or PO MMF administra-
tion. Univariate analyses did not find a correlation between
AUC, C0 or Css on Days 7 or 14 and risk of aGVHD. There
was a significant [ in MPA trough on day 7 vs 1 (P5 0.009),
[AUC on day 14 vs 7 (P5 0.049) and Y Vss day 14 vs day 1 &
7 (P5 0.001). There was also a significant [ T1/2 on day 45 vs
day 1 and 7 (P5 0.043 and P5 0.042, respectively) as well as [
CLss and Vss on day 45 vs day 14 (P5 0.01 for CLss and
P5 0.006 for Vss).
Conclusion: This change in PK parameters with time could be due
to improved mucosal healing following conditioning that leads to
improved drug absorption and enterohepatic recirculation. Based
on these results, we recommend reducing MMF dose to 600-
900 mg/m2 q8 h in the early post-transplant period in children
\12 yrs of age to target Css5 2.5-5 mg/L (Nash et al, BBMT
2005).96
EVALUATION OF THE INITIAL DOSE CALCULATION OF INTRAVENOUS BU-
SULFAN (BUSULFEX) IN ADULTS RECEIVING A CONVENTIONAL BU/
CY2 ALLOGENEIC PREPARATIVE REGIMEN
O’Neal, N.K., DuBois, L.K., Williams, C.B., Casey, K.L., Aljitawi, O.S.,
Ganguly, S., Abhyankar, S., McGuirk, J.P. The University of Kansas
Hospital, Kansas City, KS
Several studies have reported that the variability in pharmacoki-
netic (PK) parameters after intravenous busulfan dosing is signifi-
cantly lower than that recorded after dosing with the oral
formulation. However, other published experiences have concluded
that both the oral and intravenous formulation of busulfan yield wide
interpatient variability in PK parameters.MMF PO 1st sample MMF PO 2nd sample
y 114 (N5 23) Day 145-100 (N5 13) Day 145-100 (N5 7)
17.86 15.2 13.46 12.8 13.56 8.4
1.876 0.34 1.656 1.05 1.366 0.85
0.686 0.64 1.396 1.44 1.666 1.48
6.356 3.11 5.006 3.46 7.226 3.70
36.66 18.6 26.46 20.6 27.456 16.0
1.306 0.63 2.326 1.42 1.616 1.02
3.006 1.02 10.436 8.99 21.226 38.25
1.256 1.02 2.986 2.38 12.786 20.58
